Wave Life Sciences Triggers $12M Milestone Payment from GSK for siRNA Program

Key Facts

1GSK selected an siRNA program for a hepatology indication from Wave Life Sciences to transition into its development pipeline.

2The selection triggers a $12 million milestone payment to Wave Life Sciences.

3Wave is eligible for additional milestones of $330-$375 million plus tiered royalties for each collaboration program.

Wave Life Sciences announced that GSK has selected an siRNA program for a hepatology indication to transition into its development pipeline. Investing News Network reported that the selection triggers a $12 million milestone payment to Wave Life Sciences. The transition is part of an ongoing collaboration where GSK leverages Wave's proprietary SpiNA design technology for drug development.

WVE closed at $3.64 on September 29, 2026, having reached a day high of $3.78 and a low of $3.56. Under the agreement terms, Wave remains eligible for additional milestone payments ranging from $330 million to $375 million, plus tiered royalties for each collaboration program.